Form 8-K - Current report:
SEC Accession No. 0000886163-20-000105
Filing Date
2020-09-23
Accepted
2020-09-23 08:06:54
Documents
12
Period of Report
2020-09-21
Items
Item 1.01: Entry into a Material Definitive Agreement

Document Format Files

Seq Description Document Type Size
1 8-K lgnd-20200921.htm   iXBRL 8-K 38966
  Complete submission text file 0000886163-20-000105.txt   180360

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT lgnd-20200921.xsd EX-101.SCH 2430
3 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT lgnd-20200921_cal.xml EX-101.CAL 718
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT lgnd-20200921_def.xml EX-101.DEF 1655
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT lgnd-20200921_lab.xml EX-101.LAB 24270
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT lgnd-20200921_pre.xml EX-101.PRE 12654
7 EXTRACTED XBRL INSTANCE DOCUMENT lgnd-20200921_htm.xml XML 10786
Mailing Address 3911 SORRENTO VALLEY BLVD SUITE 110 SAN DIEGO CA 92121
Business Address 3911 SORRENTO VALLEY BLVD SUITE 110 SAN DIEGO CA 92121 858-550-7500
LIGAND PHARMACEUTICALS INC (Filer) CIK: 0000886163 (see all company filings)

EIN.: 770160744 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33093 | Film No.: 201190970
SIC: 2834 Pharmaceutical Preparations